Eckert & Ziegler Strahlen- und Medizintechnik AG

  • WKN: 565970
  • ISIN: DE0005659700
  • Land: Deutschland

Nachricht vom 29.07.2019 | 15:43

Eckert & Ziegler: EZAG to set up radiopharmaceutical production facility in China

DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Joint Venture/Alliance

29.07.2019 / 15:43
The issuer is solely responsible for the content of this announcement.

Press Release

Berlin, 29 July 2019 - Eckert & Ziegler Strahlen- und Medizintechnik AG (S-DAX, ISIN DE0005659700) and Chengdu New Radiomedicine Technology Co. Ltd. (CNRT) have finalized an agreement about setting up, in Chengdu, PR China, a new production facility for radiopharmaceuticals used in the treatment of hepatocellular carcinomas. The virtual joint venture will duplicate in China the manufacturing process of EZAG's existing German plant, thereby securing identical product quality and sufficient future capacity for the growing market of medical products based on Yttrium-90.

While CNRT will be primarily responsible for production, Eckert & Ziegler will be the exclusive global agent for sales and marketing and the point of contact for customers. "We are very happy to have found a strong strategic partner to provide Chinese cancer patients with effective and affordable radiopharmaceuticals", comments Andreas Eckert, CEO of Eckert & Ziegler. "Furthermore, the arrangement will allow pharmaceutical companies worldwide to receive their raw material in the familiar, consistent EZAG quality now from several facilities, thereby easing capacity and production planning".

The operational start of the new production line is timed to coincidence with the approval of various Y-90 based products for hepatocellular carcinomas that are currently under review by the Chinese authorities (CFDA).

About Eckert & Ziegler.
With around 800 employees Eckert & Ziegler Strahlen- und Medizintechnik AG is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. The core businesses of Eckert & Ziegler are nuclear-medical imaging, industrial radiometry and cancer therapy.
Contributing to saving lives.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138,,

29.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


show this


MBH Corporation. Hohes Kurspotenzial

Die MBH Corporation plc hat in den vergangenen Berichtsperioden eine sehr hohe M&A-Aktivität aufgezeigt. Unter Anwendung der so genannten Agglomeration Methodology hat die Beteiligungsgesellschaft branchenübergreifend seit 2018 11 Beteiligungen erworben. Bei einem Pro-Forma-Umsatz der Beteiligungsgesellschaften von über 120 Mio. GBP und einem Pro-Forma-EBITDA in Höhe von über 11 Mio. GBP weist die MBH derzeit eine Marktkapitalisierung von umgerechnet gerade einmal 19,8 Mio. GBP auf. Ausgehend vom aktuellen Aktienkurs liegt zu unserem Kursziel in Höhe von 1,95 € ein hohes Kurspotenzial vor

News im Fokus

Beiersdorf Aktiengesellschaft: Auswirkungen der Corona-Krise auf Geschäftsentwicklung 2020 - Beiersdorf nimmt Prognose für das Geschäftsjahr 2020 zurück

02. April 2020, 18:33

Aktueller Webcast

SeaChange Corporation

Fourth Quarter Fiscal Year 2020 Results

06. April 2020

Aktuelle Research-Studie

FinLab AG

Original-Research: FinLab AG (von Montega AG): Kaufen

03. April 2020